• Monday - Thursday: 9.00 am - 6.00 pm

What We Do & Recent Publications

WHAT WE DO & RECENT PUBLICATIONS

Our clinical trial program facilitates the new and leading treatments for patients with and without eye conditions improve clinical outcomes and patient quality of life. 

Evidenced based medicine requires diligent assessment of findings through Clinical Trials. Ophthalmic Trials Australia’s research is intent on improving the current suite of ophthalmic resources clinical practice has at is fingertips in the effort to restoring or at least, maintaining visual function. By taking time out of daily practice Mark Hinds’ team has developed Ophthalmic Trials Australia to allow medical providers to offer further clinical recommendations due to increased necessary publications and the end user new medications and innovations in clinical practice.

Ophthalmic Trials Australia assists researchers to understand eye disorders and disease processes thereby achieving the goal of improving eye health and preventing vision loss and making it available to the broader public.

Sound experimental procedures based on scientific methods conducted with consideration of several background factors covers trials using various research methods include but are not limited to: Population studies, epidemiological and observational studies. Laboratory and analytical research covering extensive background factors are welcomed.  

Under a watchful critical eye for detail and unfaltering ethical considerations Ophthalmic Trials Australia aims to improve processes, monitor outcomes and assist in discovering favourable benefits for patients and researchers alike.

Ophthalmic Trials Australia consists of easily accessible, modern facilities and state of the art equipment to conduct research in a timely fashion.  The primary advantage of our custom-built suite of testing rooms and facilities is the location with easy access to Brisbane CBD and infrastructure.  We are not limited by the many layers of management found in larger organisations such as University and Hospital based settings.  This leads to fast response times and processes limited only by external variables. 

Recent Publications & Conference Presentations

(The Association for Research in Vision and Ophthalmology) ARVO 2024: AZR-MD-001 Improved Tear Film Stability and Ocular Symptoms in Patients with Meibomian Gland Dysfunction: 6-Month Results. Joshua C. Teichman,Mark Hinds, Laura E. Downie, Yair Alster, Charles Bosworth, CELESTIAL Study Group

ARVO 2024: AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Contact Lens Discomfort in a Phase 2 Trial. Mark Hinds, Fiona Stapleton,Jacqueline Tan,Yair Alster, Charles Bosworth.

ARVO 2024: AZR-MD-001 Ophthalmic Ointment Opens Meibomian Glands, Improves Meibum Quality, and Tear Film Stability Over 3 Months of Dosing in Patients with Contact Lens Discomfort. Fiona Stapleton,Jacqueline Tan, Mark Hinds,Yair Alster, Charles Bosworth.

ARVO 2024: AZR-MD-001 Improved Corneal and Conjunctival Damage in Patients with CLD and MGD. Charles Bosworth, Mark Hinds, Eric Kassel, Yair Alster.

International Society for Contact Lens Research (ISCLR) 2024: A Patient Reported Outcome Measure for Contact Lens Discomfort Sensitive to Therapeutic Intervention in Wearers with Signs of Meibomian Gland Dysfunction. F. Stapleton, R. Chalmers, M. Hinds, J. Tan, Y. Alster, C. Bosworth

(American Society of Cataract and Refractive Surgery) ASCRS2023: AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Meibomian Gland Dysfunction (MGD): Phase 2 Responder Status. Lisa M. Nijm, Jennifer Craig, Mark Hinds,Yair Alster, Charles Bosworth; The CELESTIAL STUDY Group.

ASCRS2023: AZR-MD-001 Efficacy in Restoring Gland Function and Improving Signs and Ocular Symptoms of Meibomian Gland Dysfunction (MGD): A Phase 2 Trial. Preeya K. Gupta, Laura E. Downie, Mark Hinds, Yair Alster,Charles Bosworth; The CELESTIAL STUDY Group.

(American Academy of Optometry) AAOPT 2023: Safety and Efficacy of Topical AZR-MD-001 for the Treatment of Meibomian Gland Dysfunction: Report of the 6-Month Study Results. Fiona Stapleton, Laura E. Downie, Mark Hinds, Yair Alster,Charles Bosworth; The CELESTIAL STUDY Group.

AAOPT 2023: Sign and Symptom Improvement Rates Among MGD Patients Following 6 Months of Treatment With AZR‑MD‑001. Lyndon W. Jones, Jennifer P. Craig, Mark Hinds, Yair Alster, Charles Bosworth, Alison Ng; The CELESTIAL STUDY Group.

(American Academy of Ophthalmology) AAO 2023: Resolutions of Signs and Symptoms of Meibomian Gland Dysfunction Following 6 Months of AZR-MD-001 Treatment vs. Vehicle: A Randomized Study. Joshua C. Teichman, Lisa M. Nijm, Jennifer P. Craig, Mark Hinds, Yair Alster, Charles Bosworth; The CELESTIAL Study Group.

The Ocular Surface Volume 29, July 2023, Pages 537-546
Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial.
Stephanie L. Watson, Lyndon. Jones, Fiona Stapleton, Mark Hinds, Alison Ng, Jacqueline Tan, 
Yair Alster, Charles Bosworth, Omer Rafaeli, Venita DePuy, The CELESTIAL STUDY Group.

(The Association for Research in Vision and Ophthalmology) ARVO 2023: AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis. Lisa M. Nijm, Jennifer P. Craig, Mark Hinds, Yair Alster, Charles Bosworth; The CELESTIAL STUDY Group.

ARVO 2023: AZR-MD-001 restores gland function and improves signs and ocular symptoms of meibomian gland dysfunction (MGD). Preeya K. Gupta, Laura E. Downie, Mark Hinds, Yair Alster, Charles Bosworth; The CELESTIAL STUDY Group.